Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
QuintilesIMS
Argus Health
Fuji
Express Scripts
Cipla
Teva
Cantor Fitzgerald
Boehringer Ingelheim

Generated: April 22, 2018

DrugPatentWatch Database Preview

RYANODEX Drug Profile

« Back to Dashboard

Which patents cover Ryanodex, and what generic alternatives are available?

Ryanodex is a drug marketed by Eagle Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has eight patent family members in five countries.

The generic ingredient in RYANODEX is dantrolene sodium. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
Drug patent expirations by year for RYANODEX
Medical Subject Heading (MeSH) Categories for RYANODEX
Synonyms for RYANODEX
1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione
1-(((E)-[5-(4-Nitrophenyl)-2-furyl]methylidene)amino)-2,4-imidazolidinedione #
1-((5-(4-Nitrophenyl)furfurylidene)amino)imidazolidine-2,4-dione, sodium salt
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium salt hydrate
1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
1-[(5--(p-Nitro-phenyl)-fur-furyl-idene)-amino]-hydan-toin sodium salt
1-[(5-[p-Nitrophenyl]-furfurylidene)amino]hydantoin
1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
1-[[[5-(4-Io>>u+/-(1/2))-2-ss>>a<<>>u]NC(1/4)x>>u degrees +/->>u]-2,4-ssassosso paragraph signthornI feminine AAENI
1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione Sodium Salt Hemiheptahydrate
1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolinedione sodium salt
1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin
1-[5-(4-nitro-phenyl)-furan-2-ylmethyleneamino]-imidazolidine-2,4-dione
1-[5-(4-Nitrophenyl)furfurylideneamino]hydantoin Sodium Salt
14663-23-1
2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-
2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt
2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt, hydrate (2:7)
2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-
2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-, sodium salt, hydrate
24868-20-0
28F0G1E0VF
2C14H9N4O5.2Na
2C14H9N4O5.2Na.7H2O
7261-97-4
AB0011237
AC1O7G8U
AC1OC9NE
AKOS015895197
AKOS015895198
Ambap14663-23-1
anhydrous dantrolene sodium
B6329
BCBcMAP01_000067
BIDD:GT0187
BPBio1_000246
BRD-K81272440-001-02-6
BRD-K81272440-236-05-1
BRN 0705189
BSPBio_000222
BSPBio_001305
BSPBio_003074
C06939
C07933
C14H10N4O5
C14H9N4O5.Na
CCG-220291
CCG-40324
CHEBI:4317
CHEBI:4318
CHEMBL1201288
CHEMBL928
CPD000326766
CS-5234
D02347
D0I8DD
D3996
Dantamacrin
Dantrium
Dantrium (TN)
Dantrium Intravenous
Dantrix
Dantrolen (TN)
dantrolene
Dantrolene (sodium salt)
Dantrolene (sodium)
Dantrolene (USAN/INN)
Dantrolene [USAN:BAN:INN]
Dantrolene [USAN:INN:BAN]
DANTROLENE SODIUM
Dantrolene Sodium (anhydrous)
Dantrolene sodium [USAN:BAN:JAN]
Dantrolene sodium anhydrous
Dantrolene sodium hemiheptahydrate
Dantrolene sodium salt
Dantrolene, Sodium Salt
Dantroleno
Dantroleno [INN-Spanish]
Dantrolenum
Dantrolenum [INN-Latin]
DB01219
EINECS 230-684-8
EINECS 238-706-8
EU-0100424
F 440
F-368
F-440
F64QU97QCR
HMS1361B07
HMS1568L04
HMS1791B07
HMS1989B07
HMS2092N12
HMS2095L04
HMS3261E10
HMS3266G14
HMS3402B07
HMS502M20
HSDB 3050
HY-14657
Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-
Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt
Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt, hydrate (2:7)
I06-0335
I06-0336
IDI1_000898
IDI1_033775
Lopac0_000424
LS-174074
LS-76264
LS-76265
MFCD00079130
MLS000859905
MLS002153441
MolPort-003-666-797
MolPort-006-069-178
NCGC00093847-01
NCGC00163132-01
NCGC00163402-01
NCGC00163402-02
NCGC00163402-03
NCGC00188950-01
OZOMQRBLCMDCEG-VIZOYTHASA-N
potassium 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-4-oxo-5H-imidazol-2-olate
Prestwick2_000291
Prestwick3_000291
R452
SAM002703135
SCHEMBL12417164
SCHEMBL40893
SMR000326766
sodium 1-[(E)-{[5-(4-nitrophenyl)furan-2-yl]methylidene}amino]-4-oxo-5H-imidazol-2-olate
sodium 3-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide
sodium 3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate
Sodium dantrolene
Sodium, Dantrolene
Spectrum5_001752
ST51052737
UNII-28F0G1E0VF
UNII-F64QU97QCR
ZINC7997966

US Patents and Regulatory Information for RYANODEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for RYANODEX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,789,090 Treatment using dantrolene ➤ Sign Up
9,271,964 Treatment using dantrolene ➤ Sign Up
9,603,840 Treatment using dantrolene ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Chubb
Harvard Business School
Cipla
McKinsey
McKesson
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.